Person:
KURU, LEYLA

Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

OrgUnit Logo
Organizational Unit

Job Title

Last Name

KURU

First Name

LEYLA

Name

Filters

2017 - 20203
Reset filters

Settings

Author: AĞRALI, ÖMER BİRKAN × Subject: PREVALENCE ×

Search Results

Now showing 1 - 3 of 3
  • No Thumbnail Available
    PublicationMetadata only
    Do Platform Switching Together with Subcrestal Placement have a Benefit on Marginal Bone Levels Around Dental Implants?
    (AVES PRESS LTD, 2018) KURU, LEYLA; Agrali, Omer Birkan; Elemek, Eser; Dincer, Janberd; Kigili, Ahmet; Cilingir, Altug; Kuru, Leyla; Almas, Khalid
    Objective: The aim of this retrospective study was to assess the marginal bone levels around platform-switched dental implants placed subcrestally in partially or totally edentulous patients who had been treated in a private practice. Methods: A total of 200 implants placed in 64 patients, with a mean follow-up time of 5.3 +/- 1.7 years, were included in the study. Implants were placed 0.5 mm subcrestally via one-or two-stage surgical approach. Data regarding the distribution and diameter of the implants, the type of the prosthetic restoration, and marginal bone levels were assessed by one calibrated examiner. Results: Overall, the mean marginal bone loss was found to be 0.82 +/- 1.6 mm, and 66% of the implants (n=81) showed no bone loss, whereas 28% (n=35) showed bone loss >1mm, and 20% (n=25) showed bone loss >2mm. Out of 18 implants in use for 1-3 years, 14 of them showed no bone loss. Among implants that were in function for 3-5 years, 25% (n=15) showed bone loss >1mm, and 12% (n=7) showed bone loss >2mm. In this study, the majority of the implants were in use for more than 5 years (n=122). Out of them, 66% (n=81) showed no bone loss, whereas 28% (n=35) showed bone loss >1 mm, and 20% (n=25) showed bone loss >2mm. Conclusion: Within the limits of this retrospective study, one can say that slight amount of marginal bone loss is observed around the platform-switched implants placed subcrestally in a long-term follow-up. However, further studies are needed to confirm this finding.
  • No Thumbnail Available
    PublicationMetadata only
    Peri-implant Tissues and Diseases
    (MARMARA UNIV, INST HEALTH SCIENCES, 2017) YILDIRIM, HATİCE SELİN; Elemek, Eser; Agrali, Omer Birkan; Yildirim, Hatice Selin; Kuru, Leyla
    Peri-implant diseases occur due to imbalance between host response and biofilm after successful osseointegration of an implant with the bone. Among peri-implant diseases, peri-implant mucositis is used to describe the presence of inflammation only within the mucosa, whereas peri-implantitis is characterized by loss of supporting bone in addition to the inflammation within the mucosa. For the diagnosis of peri-implant diseases, probing depth, bleeding on probing, and suppuration are clinically assessed. Additionally, supporting bone levels are radiographically evaluated. Smoking, lack of oral hygiene, history of periodontal disease, diabetes mellitus, cardiovascular diseases, and implant surface characteristics are the known risk factors for the development of peri-implant diseases. For the treatment of peri-implant mucositis, antimicrobial treatment is performed together with mechanical debridement. However, these treatment approaches are not sufficient for peri-implantitis cases. For the treatment of peri-implantitis, resective and/or regenerative surgical interventions are used in addition to mechanical debridement. It is crucial to improve the knowledge among dentists about the prevention and progression of peri-implant diseases. On the other hand, patients should be advised regular dental visits and to maintain the highest level of oral hygiene.
  • No Thumbnail Available
    PublicationMetadata only
    The gingival crevicular fluid levels of growth factors in patients with amlodipine-induced gingival overgrowth: A pilot study
    (WOLTERS KLUWER MEDKNOW PUBLICATIONS, 2020) YILDIRIM, HATİCE SELİN; Kose, K. N.; Yilmaz, S.; Noyan, U.; Kuru, B.; Yildirim, H. S.; Agrali, O. B.; Ozener, H. O.; Kuru, L.
    Background: Amlodipine, calcium channel blocker (CCB), is used in the management of cardiovascular diseases which causes gingival overgrowth (GO). The growth factors may have a role in the pathogenesis of amlodipine-induced GO. Objectives: This pilot study aimed to investigate the growth factors including transforming growth factor-b1 (TGF-b1), platelet-derived growth factor-BB (PDGF-BB), and basic fibroblast growth factor (bFGF) in gingival crevicular fluid (GCF) of patients with amlodipine-induced GO and compare with of healthy subjects. Methods: GCF samples were collected from 56 sites presenting GO (GO + group) and from 38 sites not presenting GO (GO- group) of 5 patients using amlodipine for more than one year, and from 45 sites (control group) of 5 healthy subjects. The levels of TGF-b1, PDGF-BB, and bFGF were determined by using ELISA kits. Results: The mean concentration of TGF-b1 in GCF samples of GO + group (9.50 +/- 7.30 ng/ml) was higher than both GO- group (2.07 +/- 0.50 ng/ml) and control group (2.74 +/- 1.01 ng/ml) (P = 0.014). No significant difference was found among the groups in the GCF levels of PDGF-BB (P = 0.767). bFGF was detected in only 33% of the sites from patients. Conclusion: These preliminary results suggest that TGF-b1 may play a crucial role in the pathogenesis of amlodipine-induced GO.